Goal: to provide lasting protection of variants
deepening
Covid in Italy and in the world, the news of today 30 June. DIRECT
Their experimental vaccine work includes potentiation of T lymphocytes, especially to protect against serious disease if the virus becomes more dangerous. In presentation slides posted on BioNTech’s website on its investor day, the German firm said its goal is to “provide lasting variant protection.”
Working on a version of the Omicron vaccine
The two companies, manufacturers of the most widely used Covid vaccine in the West, are currently in discussions with regulators about improved versions of their vaccine to better protect against Omicron and its sub-variants.
As the source reports, the persistent mutation of the virus into new variants that more easily evade vaccine protection, as well as reducing human immune memory, has added urgency to the search by companies, governments and health organizations for more reliable protection tools. . BioNTech also announced that it is working on precision antibiotics that kill superbugs that have become resistant to currently available anti-infectives.